혈압강하, 어디까지 좋은가?
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신진호 | - |
dc.date.accessioned | 2021-07-30T05:28:19Z | - |
dc.date.available | 2021-07-30T05:28:19Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2016-06 | - |
dc.identifier.issn | 1738-9364 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/5025 | - |
dc.description.abstract | In general, each increase of 20/10 mmHg (systolic to diastolic) blood pressure (BP) above 115 mmHg and 75 mmHg results in a two-fold increased risk for cardiovascular complications. In addition, cerebrovascular events in association with hypertension are more frequent than myocardial infarctions in Asian populations. To prove the correlation between cardiovascular events and hypertension observed in the observational studies, BP-lowering studies should be performed to demonstrate the preventive effect on cardiovascular events. However, no randomized clinical studies to date have been able to prove the preventative effects of BP lowering in the blood pressure around 140/90 mmHg or mild hypertension. Despite the fact that many guidelines, including Joint National Committee-7 guidelines, recommend BP lowering for those ranges of blood pressure. In recent years, there have been many contradictory hypotheses about the asymmetry between the results from observational studies and clinical trials, which have led to the establishment of representative studies to set new target BPs. Such studies have proven the benefits of BP lowering closer to optimal blood pressure. Therefore, a discussion about applying these findings to patient care is needed. | - |
dc.language | 한국어 | - |
dc.language.iso | ko | - |
dc.publisher | 대한내과학회 | - |
dc.title | 혈압강하, 어디까지 좋은가? | - |
dc.title.alternative | Benefits of Intensive Blood Pressure Lowering | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | 신진호 | - |
dc.identifier.doi | 10.3904/kjm.2016.90.6.501 | - |
dc.identifier.bibliographicCitation | 대한내과학회지, v.90, no.6, pp.501 - 506 | - |
dc.relation.isPartOf | 대한내과학회지 | - |
dc.citation.title | 대한내과학회지 | - |
dc.citation.volume | 90 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 501 | - |
dc.citation.endPage | 506 | - |
dc.type.rims | ART | - |
dc.identifier.kciid | ART002114012 | - |
dc.description.journalClass | 2 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | 본태성 고혈압 | - |
dc.subject.keywordAuthor | 목표혈압 | - |
dc.subject.keywordAuthor | 진료지침 | - |
dc.subject.keywordAuthor | 항고혈압약제 | - |
dc.subject.keywordAuthor | Hypertension | - |
dc.subject.keywordAuthor | Antihypertensive drugs | - |
dc.subject.keywordAuthor | Practice guideline | - |
dc.subject.keywordAuthor | Risk assessment | - |
dc.identifier.url | https://www.ekjm.org/journal/view.php?doi=10.3904/kjm.2016.90.6.501 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.